Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Vireo Growth Earnings Call: Key Takeaways

Vireo Growth is aggressively consolidating the cannabis market through acquisitions, achieving a $1 billion revenue run rate while pivoting to formal sequential guidance and disciplined cost management.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthQ3 revenue $253.7M, up 177% YoY; Florida retail grew 34% QoQ.
Mgmt ConfidenceHigh confidence in turnaround strategy; providing first-ever formal sequential quarterly guidance.
Demand VisibilityVisibility limited to immediate operational horizons; sequential guidance adopted for agility.
Margin TrendsAdjusted EBITDA $42.7M; Q4 guidance 18% margin; Q1 2027 margin 18.8%.
Op. LeverageLeveraging scale to drive performance; shared services across THC and non-THC.
Pricing PowerFacing mid-single digit cannabis price deflation; retail same-store growth at 4%.
Vol vs PriceGrowth driven by M&A volume; retail organic growth 4% despite deflation.
Segment GrowthFlorida up 34%; Minnesota down 10%; Colorado now 25% of retail.
New ClientsAcquired Pharmacan Colorado, C-21, M-3 Wellness, and Fluent Florida operations.
Capex & DebtNet debt $166.2M; $60M real estate loan at 8.5% fixed rate.
RegulatoryMonitoring DEA registrations in Florida and pending approvals in Ohio.
CommentaryFocus on 'boiling a million eggs'—executing simple retail excellence at scale.
New LaunchesExpanding into Ohio; opening second cultivation facility in Minnesota.

Growth

Q3 revenue rose 177% year-over-year to $253.7 million; pro-forma revenue reached $277 million.

Outlook

Q4 2026 revenue guided to $250M-$265M; Q1 2027 revenue guided to $280M-$300M.

Risks

Management pivoted on Minnesota's 10% retail decline, blaming supply issues and lack of flower.

Source

The company's earnings call, OTC: VREOF, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Vireo Growth Inc.: key numbers

Share price
$6.29Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Vireo Growth Inc.

All →
4:02 PM ET 10-Q
Financial Results

Vireo Growth Q3 2026 Results: Net Loss of $24M, Loss Narrows

Vireo Growth Inc. reported a significant revenue increase to $253.7 million for the quarter ended September 30, 2026, compared to $91.7 million in the prior year, driven by multiple acquisitions including Eaze, Hawthorne, and C21. Despite higher gross profits, the company recorded a net loss of $24.0 million for the quarter, impacted by substantial current income tax expenses and transaction-related costs.

Key figure
Net loss $24M
7:30 AM ET 8-K
Financial Results

Vireo Growth Financial Results

Vireo Growth reported Q3 2026 GAAP revenue of $253.7 million, a 177% increase year-over-year driven by recent M&A activity. The company achieved an annualized revenue run rate exceeding $1 billion and ended the quarter with $106.8 million in cash. Management highlighted the continued execution of its consolidation strategy and the pending merger with Planet 13.

Term
Q3 2026
4:06 PM ET 8-K
Loan & Debt

Vireo Growth $60M Debt Financing with Needham Bank

Vireo Growth Inc. entered into a $60 million term loan agreement with Needham Bank at a fixed interest rate of 8.50% per annum. The proceeds were used to refinance $49 million of existing senior debt related to its New York cultivation facility and to finance the $11 million acquisition of its Palatka, Florida cultivation facility. The loan is secured by first-priority mortgages on these properties and matures in April 2034.

Value
$60M
Counterparty
Needham Bank
Term
through April 2, 2034

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.